News

March 15, 2021

Agile BioFoundry, Lygos will Generate the Largest Multi-Omics Dataset to Accelerate Machine Learning Capabilities for Organic Acid Development

Scientists will generate more than 500,000 data points to help optimize strain performance, increase operational efficiencies and improve production for malonic acid.

February 19, 2021

Case Study: Producing High-Value Chemicals from Renewable Sources

Biotechnology company Visolis teamed up with the Agile BioFoundry to explore new feedstocks and microbes that are cheaper, more reliable, and perform well.

January 26, 2021

Agile BioFoundry Launches New Website

Our website has been updated to better communicate our mission, collaborations, and capabilities.

January 21, 2021

Agile BioFoundry Announces 2021 Directed Funding Opportunity

The Agile BioFoundry is overseeing a directed funding opportunity for industry and academic partners to utilize our capabilities.

January 17, 2021

Agile BioFoundry to Participate in Global Biofoundries Alliance Webinar Series

Agile BioFoundry data scientist Tijana Radivojevic will participate in the first GBA webinar of 2021.

October 05, 2020

Agile BioFoundry Research Wins R&D 100 Award

Smart Microbial Cell Technology is a high throughput screening platform for enzymes and whole cell biocatalysts.

September 28, 2020

Help Improve the Agile BioFoundry

We are requesting information that will allow us to better understand and serve the biomanufacturing industry.

September 25, 2020

Machine Learning Takes on Synthetic Biology: Algorithms Can Bioengineer Cells for You

A new tool could drastically speed up the ability to design new biological systems.

July 10, 2020

Agile BioFoundry Selects New Projects to Accelerate Biomanufacturing

DOE announced the selection of eight projects totaling over $5 million to conduct research and development needed to accelerate the US biomanufacturing sector.

April 06, 2020

Agile BioFoundry Capabilities Available to Support COVID-19 Efforts

Our capabilities can be applied to the development of new therapeutics and diagnostics in the nation's response to the COVID-19 pandemic.